Summarized by Daily Strand AI from peer-reviewed source
Alzheimer's disease research is entering a busy new chapter. As of early 2025, scientists are running more than 180 clinical trials to find better ways to treat the condition. Much of the recent spotlight has been on immunotherapies, which harness the immune system to fight the disease. Specifically, drugs like lecanemab and donanemab target and reduce clumps of a protein in the brain called amyloid beta. These protein clumps, known as plaques, are a major hallmark of Alzheimer's.
While clearing these plaques is a significant scientific step, researchers are careful to note the limitations of current treatments. For patients in the early stages of the disease, these amyloid-targeting drugs only modestly preserve memory and daily functioning. Because of this, scientists are also testing treatments aimed at tau, another protein that causes problems in the Alzheimer's brain. Early studies of tau-targeted vaccines, antibodies, and genetic tools called antisense oligonucleotides show that these experimental treatments are generally well tolerated by patients.
The sheer volume of ongoing trials reveals a major shift in how the medical field approaches Alzheimer's disease. Scientists are testing a wide variety of strategies across different stages of the illness, even reaching out to at-risk populations before severe symptoms ever appear. This diversified strategy offers hope for aging populations worldwide, suggesting that future medicine might tackle the disease from multiple angles before it can cause permanent damage.
However, discovering new biology is only half the battle. A major hurdle remains in bringing these scientific breakthroughs into everyday medical care. Researchers caution that despite a vastly expanded understanding of the genetics, biological markers, and physical brain changes associated with Alzheimer's, there is a significant lack of implementation in real-world clinical practice. Bridging the gap between the laboratory and the local clinic will be essential to ensure these new therapies actually benefit patients.
Interested in Drug Development?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.